Trilogy Capital Inc. Gilead Sciences, Inc. Transaction History
Trilogy Capital Inc.
- $1.87 Billion
- Q1 2025
A detailed history of Trilogy Capital Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 33,247 shares of GILD stock, worth $3.42 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
33,247
Previous 37,307
10.88%
Holding current value
$3.42 Million
Previous $3.45 Million
8.1%
% of portfolio
0.2%
Previous 0.18%
Shares
26 transactions
Others Institutions Holding GILD
# of Institutions
2,203Shares Held
992MCall Options Held
8.66MPut Options Held
9.39M-
Black Rock Inc. New York, NY121MShares$12.4 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA117MShares$12.1 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.37 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.21 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$5.96 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $129B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...